InvestigationalApproved non-peptide GLP-1

Orforglipron

Also known as:Foundayo (brand context)LY3502970

Class: Approved non-peptide GLP-1
Route: Oral tablet
Frequency: Once daily
GLP-1 relevance: Yes

How it works

Oral small-molecule GLP-1 receptor agonist (not a peptide)

Approved & studied uses

Chronic weight management / diabetes pipeline-product depending region

Regulatory status

Regulatory status varies by jurisdiction; not confirmed as FDA-approved as of 4 August 2026

Safety notes

A non-peptide small-molecule GLP-1 receptor agonist, not a peptide.

Sources

Orforglipron Lilly

Educational reference only. This page does not provide diagnosis, dosing, titration or treatment recommendations. Peptimize does not recommend or adjust any medication schedule - that is between you and your prescriber.